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Idiopathic Pulmonary Fibrosis (IPF) is characterized by alveolitis with epithelial, endothelial
damage leading to fibrosis. As signaling of endothelin-1 was involved in IPF, the effect of bosentan
a non-specific endothelin receptor antagonist was determined in a mouse model of bleomycin
induced pulmonary fibrosis. In the present study, mice were instilled with intra-tracheal instillation
of bleomycin (0.05U) and were administered with bosentan at 100 mg/kg body weight. The
treatment with bosentan significantly (p ≤ 0.05) prevented bleomycin induced mortality and loss
of body weight. On day 7, bosentan significantly (p ≤ 0.05) attenuated bleomycin induced increase
of total and differential inflammatory cell counts, total proteins, edema, MPO activity and
inflammatory cell infiltration in lung tissue. The activities of superoxide dismutase and catalase
were restored by bosentan treatment which lowered in bleomycin administered mice. Bosentan
treatment significantly attenuated bleomycin induced increase in fibrosis score, collagen
deposition and hydroxyproline levels. On day 21, treatment with bosentan significantly attenuated
α-smooth muscle actin and collagen-I gene expression levels and matrix metalloproteinases 2
and 9 activities. The results revealed that bosentan exerted enhanced protection against bleomycin
induced inflammation and fibrosis.
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INTRODUCTION
Idiopathic Pulmonary Fibrosis (IPF) is one of the
most common forms of interstitial lung disease
and is characterized by alveolar damage and
increased scar tissue production that results in
fibrous destruction of lung parenchyma and
subsequent lung dysfunction (Wilson and Wynn,
2009). Currently 5 million people worldwide are
affected by the IPF with over 200,000 patients in
United States and median survival time is
approximately 3-5 years (Raghu et al., 2006).
Although etiology of IPF has not been clearly
under stood, its principal pathologic
characteristics include epithelial and endothelial
damage, inflammation followed by the
proliferation of type II pneumocytes and fibroblasts58
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leads to collagen deposition. The pathogenesis
of IPF is complex, involving mediators, cytokines
and growth factors produced by a variety of cells
within the lung (Crystal et al., 1984). One potential
mediator is endothelin-1 (ET-1), a vasoactive
peptide first isolated and purified from the culture
medium of porcine aortic endothelial cells
(Yanagisawa et al., 1988; Inoue et al., 1989). The
effects of ETs are mediated by two principal
specific receptors, ET-A, which has a
substantially greater affinity for ET-1 than ET-2
and ET-3 (Arai et al., 1990), and ET-B, with a
similar affinity for ET-1, -2, and -3 (Sakurai et al.,
1990). ET-1 is well known for the potent
vasoconstrictor activity, but it also serves as a
bronchoconstrictor, chemoattractant, fibroblast
cell mitogen, and stimulant of collagen synthesis
(Fagan et al., 2001). ET-1 has been extensively
implicated in the pathogenesis of pulmonary
fibrosis. Patients with scleroderma have elevated
levels of ET-1 in plasma, Bronchoalveolar Lavage
Fluid (BALF) and lung tissue (Kadono et al., 1995;
Cambrey et al., 1994). In IPF patients, plasma
ET-1 levels are elevated (Uguccioni et al., 1995)
and histological expression correlates with
disease severity (Uguccioni et al., 1995; Saleh et
al., 1997). Intra-tracheal administration bleomycin
increases (Mutsaers et al., 1998; Hocher et al.,
2000). ET-1 in the lung may be important in the
initial events in lung injury by activating neutrophils
to aggregate, release of oxygen radicals and
cytokine production (Helset et al., 1996; Ishida et
al., 1994; Helset et al., 1994). Transforming
growth factor-β1 (TGF- β1) and tumor necrosis
factor-α (TNF-α) are key profibrotic cytokines
induced by ET-1 (Khalil et al., 1989; Piguet et al.,
1989). It is also profibrotic by stimulating fibroblast
replication, migration, collagen synthesis and
conversion of fibroblasts into contractile
myofibroblasts (Shahar et al., 1999). ET-1 may
thus play an important role in the initial injury,
inflammatory and eventual fibrotic reparative
process of lung. We hypothesized that ET-1 is
an important mediator in pulmonary fibrosis,
hence present study was designed to investigate
the potential protective effect of bosentan-non
specific ET receptor antagonist in bleomycin
induced pulmonary fibrosis in mice
MATERIALS AND METHODS
Reagents
Bleomycin sulfate and bosentan were purchased
from Sigma, USA, and all other chemicals used
for the present study were purchased from
Himedia (Mumbai, India).
Experimental Animals and Dosing
Healthy, female C57BL/6J mice weighing 20-23
g were purchased from National Institute of
Nutrition (Hyderabad, India). All the animals were
housed in polypropylene cages in pathogen free
experimental rooms and were maintained at a
room temperature of 22 ± 3oC and relative
humidity of 55 ± 6% with 12:12 h light/dark cycles
for one week prior to experiment. Food and water
were provided ad libitum. All the experiments were
performed in accordance with the Institutional
Animal Ethics Committee (IAEC). After
randomization, the animals were divided into three
groups and were anesthetized with intra-
peritoneal injections of ketamine and xylazine
at100 and 10 mg/kg body weight respectively.
Using aseptic techniques, a single incision was
made at the neck, and the muscle covering the
trachea was snipped to expose the tracheal rings.
A single intratracheal instillation of 0.05 U
bleomycin sulfate in 50 µL of sterile 0.9% NaCl
was performed using a 27-gauge needle for each59
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animal. Following were set of groups for the
present study; Group- I animals were received
intra-tracheal instillation of sterile 0.9% NaCl at
day 0 and was given vehicle - 0.5% carboxymethyl
cellulose through oral gavage. Group- II animals
were received intra-tracheal instillation of
bleomycin at day 0 and were given vehicle alone.
Group- III animals were received intra-tracheal
instillation of bleomycin and were administered
with bosentan at 100 mg/kg b.wt in vehicle by
oral gavage at dosage volume of 10 mL/kg b.wt
three days prior to intratracheal bleomycin
instillation and continued daily once up to 21 days
after bleomycin instillation. Appropriate numbers
of mice were sacrificed on day 7 and 21 after
bleomycin administration. BALF was collected for
cell analysis and the remaining supernatant was
stored at -20°C for further analysis. Right lung
was excised and stored at -80oC for biochemical
assays. Left lung was collected and stored in
10% neutral buffered formalin for histological
analysis.
BALF Cell Analysis
Briefly, on day 7 of post bleomycin instillation the
mice were euthanized and the trachea was
immediately cannulated with intravenous
polyethylene catheter equipped with 24-gauge
needle attached to 1 mL syringe. The lungs were
lavaged with 0.8 mL of PBS each time for four
times and withdrawn from the lungs via an
intratracheal cannula. The recovery volume was
approximately 0.7 mL each time. The lavage fluids
were pooled and centrifuged at 1000 rpm for 10
min at 4oC and the supernatant was collected
and stored at –20oC until further use. The cell
pellets were re-suspended in 1 mL of PBS, and
10 or 20 µL of cell suspension was used to
enumerate cell population using hemocytometer
in the presence of trypan blue. The microscopic
slides were prepared manually and stained with
5% Giemsa. Differential counting was performed
by counting at least 400 cells from randomly
chosen areas for each sample and the results
were expressed as total number of cells/mL
(Furonaka et al., 2009).
Measurement of Fluid Content in Lung
The right lung was carefully excised, and wet
weight was measured. Subsequently, the lung
was dried for 24 h at 60°C, and its dry weight
was measured. The ratio between wet and dry
lung weight is the measure of edema formation.
Superoxide Dismutase (SOD) Assay
SOD activity was measured based on the ability
of the enzyme to inhibit superoxide anion
dependent autoxidation of pyrogallol. The 10%
homogenate of lung tissues was prepared in 50
mM sodium phosphate buffer (pH 7.2) using
mortar and pestle. Cytosolic extracts were
isolated from homogenates by employing
centrifugation at 12,000 rpm for 30 min at 4oC. To
0.1 mL of cell extract (400 µg of protein) prepared
in 50 mM sodium phosphate buffer (pH 7.2), 0.7
mL of 50 mM Tris (pH 8.0) 0.1 mL of 10 mM
diethylaminetriamine pentaacetic acid and 0.1 mL
of 10 mM pyrogallol were added, increase in
optical density was monitored for 3 min at 420
nm with UV Visible spectrometer (Shimadzu,
Japan). One unit of SOD is defined as the amount
required to inhibit 50% pyrogallol auto oxidation
per min under defined assay systems (Manikonda
et al., 2012). The results were expressed as
units/gram tissue.
Catalase Assay
The reaction mixture containing 20 mM hydrogen
peroxide in 50 mM sodium phosphate buffer (final60
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volume 3 mL) was added to the cytosolic extract
(0.2-0.4 mg protein). The change in absorbance
was monitored after 5 min at 240 nm in UV Vis
spectrophotometer (Shimadzu, Japan). One unit
of catalase activity is defined as the activity
required for decomposing 1 μmol of hydrogen
peroxide per min per mg protein at pH 7.0 and at
25oC (Manikonda et al., 2012). The results were
expressed as units/gram tissue.
Myeloperoxidase (MPO) Assay
Ten percent homogenates of lung tissues were
prepared in 50 mM phosphate buffer (pH 6.0)
containing 0.5% of hexadecyltrimethyl ammonium
bromide using mortar and pestle. The
homogenate samples were subjected to three
freeze-thaw cycles and centrifuged at 15,000 rpm
for 20 min. 0.1 mL of the supernatant combined
with 1.8 mL 50 mM phosphate buffer (pH 6.0)
containing 0.167 mg/mL O - dianisidine
hydrochloride and 0.0005% of hydrogen peroxide.
The change in absorbance for 5 min at 465 nm
was measured with spectrophotometer
(Shimadzu, Japan). One unit of myeloperoxidase
activity is defined as that degrading 1 µmol of
peroxide per minute at 25oC (Yan et al., 1998).
The results were expressed as u/mg tissue.
Hydroxyproline Assay
Hydroxyproline content of lungs was determined
as a biochemical quantitative measure of
collagen deposition, was determined as previously
described (Wossner et al., 1961). The 10%
homogenates in PBS (pH 7.4) were hydrolyzed
with 6 N hydrochloric acid (HCl) at 120oC for 8 h.
One milliliter of 0.05 M chloramine -T solution was
added to acid extract and incubated for 20 min at
room temperature and 1 mL of Ehrlich’s solution
was added and incubated for 20 min at 65oC. The
samples were cooled and the OD was read at
550 nm. The data was expressed as μg of
hydroxyproline/g tissue as determined by the
standard curve.
Reverse Transcriptase - PCR
For determining the steady state levels of mRNA
expression, a semiquantitative-PCR was
performed. Total RNA was extracted from the lung
tissues with TRIzol reagent (Fermentas)
according to the instructions of the manufacturer.
The concentration of total RNA was calculated
by measuring OD at A260. The first strand of
cDNA was synthesized using 2 μg of RNA in 20
μL of reaction buffer by reverse transcription using
RevertAid M-MuLV Reverse Transcriptase and
oligo (dT) primer (RevertAid First Strand cDNA
Synthesis Kit, Thermo Scientific). Aliquots of total
RNA (1.0 μg) from each sample was transcribed
into cDNA by revertide cDNA synthesis kit
(Fermentas) according to the instructions of
manufacturer. PCR was carried out using a
standard PCR kit on 2 μL aliquots of cDNA and
Taq polymerase using gene specific primers.
About 20 to 25 cycles at 94oC for 1 min, 55oC for
1 min, and 72oC for 1 min for amplification in the
linear range were used, followed by a final
extension step at 72o C for 7 min. The PCR
products were size fractionated on agarose gels
and detected by ethidium bromide staining. Band
intensities were quantified by the densitometry
using Image J software (NIH, Bethesda, MD,
USA). The sequences of primer sets are specified
as follows, collagen-I 5' GAGCGGAGA
GTACTGGATCG 3' (sense) and 5'TACTCGAAA
CGGGAATCCA 3'(antisense); α-SMA 5'CAGGGA
GTAATGGTTGGAAT 3' (sense) and 5'TCTCAAA
CATAATCTGGGTCA 3'(antisense); β-actin
5'TGCGTGACATCAAAGAGAAG 3' (sense) and
5'GATGCCACAGGATTCCATA 3'(antisense).61
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Measurement of MMPs by Gelatin
Zymography
MMPs have been shown to actively participate in
the pathogenesis of IPF through ECM degradation
and basement disruption facilitating proliferation
and migration of inflammatory cells and
fibroblasts. MMP-2 and MMP-9 are the two major
gelatinases elevated in IPF patients (Pardo and
Selman et al., 2006). To determine the MMP-2
and MMP-9 activities gelatin zymography was
performed as described (Sumii et al., 2002).
Briefly, 10% homogenates of lung tissues was
prepared in lysis buffer (50 mM Tris HCl, 150 mM
NaCl and 1% Triton X-100, pH 7.4). The total
protein concentration of clear supernatants was
determined by the Bradford reagent (Bio-Rad
Laboratories). Homogenate containing 20 μg of
total protein was mixed with 2X non-reducing SDS
PAGE sample buffer (126 mM Tris-HCl pH 6.8,
20% glycerol, 4% SDS, 0.005% bromophenol
blue) and electrophoresed in 10% polyacrylamide
gel containing 2 mg/mL gelatin. Following
electrophoresis, gels were washed twice for 20
min with 2.5% Triton X-100 in Tris buffered saline
(50 mM Tris HCl, pH 7.5, 150 mM NaCl) buffer to
allow protein to renature. Gels were then
incubated for 18-20 h at 37°C in incubation buffer
(50 mM Tris HCl, pH 8, 10 mM CaCl2, and 0.02%
NaN3), stained with Coomassie R 250 for 30 min
and destained for 1 h. Gelatin-degrading enzymes
were visualized as clear bands, indicating
proteolysis of the substrate protein. Band
intensities were quantified using Image J software
analysis (NIH, USA).
Histological Assessment
Lung tissues were collected on day 7 and 21 after
bleomycin instillation. Tissues were fixed for one
week in 10% (w/v) PBS-buffered formaldehyde
solution at room temperature, dehydrated using
graded alcohol and embedded in paraffin wax.
After the tissues were embedded in paraffin and
tissue sections were prepared and stained with
hematoxylin and eosin for morphometric analysis,
trichrome staining and picrosirus red staining
were performed to assess the severity of fibrosis.
The severity of fibrosis was semiquantitatively
assessed according to the method described by
Ashcroft et al. (1988).
RESULTS
Effect of Bosentan on Body Weights and
Mortality of Mice in Bleomycin Induced
Pulmonary Fibrosis
The severe lung injury caused by the bleomycin
instillation was associated with high mortality and
reduction of body weights. Bleomycin instillation
reduced the survival rate (47%; 7 survived out of
15 animals) of mice (Figure 1A). In contrast,
bosentan administration significantly (p ≤ 0.05)
increased survival rate by 80% in bleomycin
induced mice. Further, the body weights of control
animals were increased during 21 days.
Conversely, the body weights of bleomycin
induced pulmonary fibrotic mice were decreased
during 21 days of study (Figure 1B). However,
the loss of body weights was increased by the
bosentan treatment.
Effect of Bosentan Administration on
Bleomycin Induced BALF Inflammatory
Cells in Mice
To evaluate the effect of bosentan in bleomycin
induced inflammation, the number of
inflammatory cells in BALF at day 7 after
bleomycin instillation was measured. The total
number of inflammatory cells in BALF were
significantly (p ≤ 0.05) increased by 4.8 fold in62
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Figure 1: Effect of bosentan on body weight loss and survival rate. Pulomnary fibrosis was
induced with 0.05 U bleomcyin/mice. 100 mg/kg b.wt of bosentan was adminstered orally for
21 days post bleomcyin instillation. The survival rate (A)  and body weight (B) were measured
in each group. Bleomycin induced group was compared with respective control as well as
bosentan adminstered group. Results were expressed as Mean ± SD obtained from survival
animals (initial number of animals n=15) per group (p ≤ ≤ ≤ ≤ ≤ 0.05)
bleomycin instilled mice when compared to
respective controls (Figure 2A). However
bosentan administration significantly (p ≤ 0.05)
decreased the inflammatory cells by 43.7%
compared to belomycin group. In addition, the
differential count of cells present in BALF has
shown a drastic increase of lymphocytes
(6.5 fold), macrophages (3.0 fold) and neutrophils
(13.5 fold) (p ≤ 0.005) in bleomycin induced
pulmonary fibrotic mice compared to respective
controls (Figure 2B, 2C and 2D). Where as the
treatment with bosentan significantly (p ≤ 0.05)
decreased the lymphocytes, macrophages and
neutrophils by 40%, 42.3% and 53%, respectively.
In addition to the inflammatory cells, the total
protein levels in BALF have significantly (p ≤ 0.05)
increased by 3.0 fold in bleomycin instilled mice
compared to respective controls. These elevated
levels of protein significantly decreased (p ≤ 0.05)
by 41% in bosentan treated mice compared to
bleomycin instilled mice (Figure 3C).
Effect of Bosentan on Oxidative Stress
Induced by Bleomycin
The present investigation focussed on oxidative
stress indicators such as SOD, and catalase in
bleomycin induced lung fibrotic mice. As shown
in Figure 3A, the SOD activity was significantly
(p ≤ 0.05) decreased by 47% in bleomycin instilled
mice compared to controls. However, the SOD
activity was restored by 31.5% in bosentan treated
mice compared bleomycin group. Similarly way
the catalase activity was significantly decreased
by 59% in bleomycin instilled mice compared to
saline instilled mice. In contrast bosentan
administration significantly (p ≤ 0.05) increased
the catalase activity by 78% compared to
bleomycin group (Figure 3B).
Effect of Bosentan Administration on
Inflammatory Cells Infiltration in Lung
Tissues of Bleomycin Induced Mice
Hematoxylene and eosin staining of lung tissues
revealed that a well alveolized normal lung
structure was seen in control mice. In contrast63
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bleomycin induced mice showed evident tissue
damage, and extensive infiltration of inflammatory
cells on day 7 (Figure 4A). However, this massive
infiltration of inflammatory cells was reduced in
bosentan administered mice. Severe epithelial
degeneration, excessive deposition of
extracellular matrix proteins and distorted alveolar
architecture were observed in the lungs of
bleomycin instilled mice on day 21 (Figure 4B).
Whereas in lungs of bosentan administered mice
showed reduced epithelial degeneration,
extracellular matrix deposition and restored
alveolar architecture when compared to the mice
administered with bleomycin alone.
Since, myeloperoxidase (MPO) activity is the
marker of lung infiltration with polymorphonuclear
neutrophils, the MPO activity was measured in
the lungs of bleomycin induced pulmonary fibrotic
mice. Bleomycin caused 8.9 fold increase in MPO
activity significantly (p ≤ 0.05) in lung tissues
compared to the saline instilled mice (Figure 4C).
However, the administration of bosentan in
bleomycin induced pulmonary fibrotic mice
decreased the MPO activity by 31% compared
to the bleomycin group (Figure 4C).
Lung wet/dry weight ratio is an indicator of
tissue edema (inflammatory response) which
Figure 2: Effect of bosentan on bleomycin induced inflammation in BALF. Pulomnary fibrosis
was induced with 0.05 U bleomcyin/mice. BALF fluid was collected on day-7, total cell
count (A), lymphocytes (B), macrophages (C) and neutrophils (D) differential cell counts
were performed. Bleomycin induced group was compared with respective control as well
as bosentan adminstered group. Results were expressed as Mean ± SD, n=5-6  and***
indicates the statistical significance (p ≤ ≤ ≤ ≤ ≤ 0.001) between control and bleomycin groups.
* indicates the statistical significance (p ≤ ≤ ≤ ≤ ≤ 0.05) between bleomycin group
and treatment groups64
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Figure 3: Effect to bosentan on SOD and catalase activities changes by bleomycin
administration and total protein level in BALF fluid.  SOD & catalase activity in control
and bleomycin instilled mice with and with out bosentan adminstration (A). Total protein
levels in control and bleomycin instilled mice with and with out bosentan adminstration (C).
Data represented as mean SD± values, n=5-6. *** indicates the statistical significance
(p ≤ ≤ ≤ ≤ ≤ 0.001) between control and bleomycin groups. * indicates the statistical significance
(p ≤ ≤ ≤ ≤ ≤ 0.05) between bleomycin group and treatment groups
Figure 4: The H&E staining images on day-7 (A) showed that extensive inflammatory cell
infiltration in bleomycin instilled mice where as it was decreased by bosentan administration.
H&E staining images at day-21(B) revealed that higher deposition of collagen in mice instilled
with bleomycin alone where as it was decreased in mice treated with bosentan. All Images
were represented as 40X magnifications. Bleomycin instilled mice elicited significant
increase in MPO activity in lung tissues (C) and wet/dry lung weight ratio (D).
Bosentan significantly decreases the MPO and wet/dry lung weight ratio on day-7 after
bleomycin instillation. Data represented as mean SD± values, n=5-6. *** indicates the
statistical significance (p ≤ ≤ ≤ ≤ ≤ 0.001) between control and bleomycin groups. * indicates the
statistical significance (p ≤ ≤ ≤ ≤ ≤ 0.05) between bleomycin group and treatment groups.
Black arrow indicates inflammatory cells in (A) and collagen deposition in (B)65
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was characterized by the accumulation of water
in lungs. Intratracheal bleomycin instilled mice
showed a 40% increase in lung wet/dry weight
ratio compared to saline instilled mice. However,
treatment with bosentan at 100 mg/kg significantly
decreased the lung wet/dry weight ratio by 21%
compared to bleomycin instilled mice (Figure 4D).
Effect of Bosentan on Hydroxyproline
Levels and Tissue Fibrosis Elevated by
Bleomycin Instillation
Hydroxyproline is a modified amino acid uniquely
found at high percentage in collagen. Therefore,
the tissue hydroxyproline content of lungs was
assessed as a biochemical quantitative measure
of collagen deposition. Hence, we have analyzed
the hydroxyproline content in mice lungs at day
21. As shown in Figure 5C the hydroxyproline
content was significantly (p ≤ 0.05) increased by
2.6 fold in bleomycin instilled mice compared to
saline instilled mice. However in mice
administered with bosentan at 100 mg/kg showed
significant (p ≤ 0.05) decrease in collagen content
by 33.1%.
Pulmonary fibrosis was evaluated by light
microscopy using sections stained with Masson’s
trichrome stain or picrosirus red stain. As shown
Figure 5: Effect of bosentan on the collagen accumulation induced by bleomycin. The trichrome
staining images (A) and picrosirus red staining images (B) on day-21 showed the excessive
deposition of collagen in lung tissue sections of bleomycin instilled mice where as it was
decreased by bosentan administration. All Images were represented as 10X magnifications.
Bleomycin instilled mice demonstrated significant increase in lung hydroxyproline levels (C)
and fibrosis score (D). Bosentan significantly decreases the collagen and fibrosis score on
day-21 after bleomycin instillation. Data represented as mean SD± values, n=5-6. *** indicates
the statistical significance (p ≤ ≤ ≤ ≤ ≤ 0.001) between control and bleomycin groups. * indicates the
statistical significance (p ≤ ≤ ≤ ≤ ≤ 0.05) between bleomycin group and treatment groups66
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in Figure 5A, Masson’s trichrome staining of lung
tissues showed an excessive deposition of
collagen which was stained as blue color in mice
instilled with bleomycin compared to saline-
instilled mice. Such observations were decreased
in bosentan treated mice at dose level of 100 mg/
kg indicating the protective role of bosentan in
pulmonary fibrosis. The scores of fibrosis
significantly increased in bleomycin instilled mice
compared to those of normal control mice.
However, bosentan administration significantly (p
≤ 0.05) lowered the fibrosis score. Similarly, as
shown in Figure 5B, picrosirus red staining also
showed a similar pattern of collagen deposition
in bleomycin treated animals, while this collagen
deposition was reduced in mice treated with
bosentan.
Bosentan Administration Attenuated α α α α α-
SMA and Collagen-I Gene Expression in
Lung Tissue of Bleomycin Induced Mice
RT- PCR analysis showed that the expression
level of collagen-I and α-SMA genes were
significantly increased by 12.1 fold and 10.2 fold
(p ≤ 0.05) in bleomycin instilled mice compared
to saline-instilled controls. The administration of
bosentan at 100 mg/kg significantly decreased
the expression levels of α-SMA and collagen-I
genes by 38% and 49% respectively when
compared to bleomycin instilled mice (Figure 6).
Effect of Bosentan on the MMP-2 and
MMP-9 Activities in Fibrotic Mice Lungs
Induced by Bleomycin
To investigate the activity of MMP-2 and MMP-9
Figure 6: Effect of bosentan on the gene expression levels of collagen-I and α α α α α-SMA.
Pulmonary fibrosis was induced with 0.05 U bleomcyin/mice and bosentan was administred
for period of 21 days. Lung tissues will be collected on day-21 total RNA was isolated and
converted to C-DNA. Semiquantitative RT-PCR  was performed to measure the mRNA levels
of collagen-I and α α α α α-SMA and data were expressed as a relative change compared to control
for each gene. β β β β β- actin gene products were used to control for quality and equal loading of
c-DNA. *** indicates the statistical significance (p ≤ ≤ ≤ ≤ ≤ 0.01) between control and bleomycin
groups. * indicates the statistical significance (p ≤ ≤ ≤ ≤ ≤ 0.05) between bleomycin group
and treatment groups67
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in the lungs of mice we have performed gelatin
zymography of extracted proteins from lungs on
day 14. As shown in figure, the mice instilled with
bleomycin exhibited increased relative density of
Pro MMP-2 as well as active MMP-2 by 6.8 and
12.2, respectively when compared to saline-
instilled mice. Pro MMP-9 as well as active MMP-
9 activities were increased by 6.8 and 12.2
respectively when compared to saline-instilled
mice. However the administration of bosentan
decreased (p ≤ 0.05) relative density of Pro MMP-
2 as well as active MMP-2 to 1.4 and 2.6,
respectively compared to saline-instilled control.
Where as the relative densities of Pro MMP-9 as
well as active MMP-9 activities were decreased (p
≤ 0.05) to 4.1 and 8.4 respectively when compared
to saline-instilled mice (Figure 7).
DISCUSSION
The main findings of the present study are that
the intervention with ET-1 receptor antagonist
bosentan suppresses the development of
pulmonary fibrosis induced by the bleomycin
challenge. Bosentan reduced the body weight
loss, mortality, suppressed the early
inflammation, improved antioxidant ability,
reduced the MMP-2 and MMP-9 activities, and
finally attenuated the fibrosis of lung tissue. The
paracrine lung ET system is thought to be
involved in the pathogenesis of several lung
diseases such as primary and secondary
pulmonary hypertension (Giaid and Saleh, 1995;
Lutz et al., 1999) pulmonary fibrosis (Mutsaers
et al., 1998) asthma and chronic obstructive lung
Figure 7: Identification of gelatinolytic activity activities in lung tissues (A).
Supernatants from lung tissue extracts derived from bleomycin instilled, administred
bosentan after bleomycin instillation and control animals were resolved by SDS PAGE
(10%) containing 3mg/ml gelatin. Zone of genolytic activity appear as a clear bands over
dark background. Densitometric analysis were performed data expressed as a relative
change compared to control for each gene. # and * indicates the statistical significance  of
control  (p ≤ ≤ ≤ ≤ ≤ 0.05) compared to the bleomycin groups and bleomycin compared to
treatment groups respectively68
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disease (Hay, 1999) and bronchiolitis obliterans
(Takeda et al., 1997; Schersten et al., 1996).
Activated Paracrine ET-1 caused increased
pulmonary matrix synthesis and a chronic
inflammatory lung disease characterized by an
increased infiltration of CD-4 positive cells
(Hocher et al., 2000). Several pro-inflammatory
mediators like interleukin (IL)-1α, IL-1β and tumor
necrosis factor-α are known to stimulate the ET
system (Hocher et al., 1997, Nakano et al., 1994).
It has also been postulated that ET-1 it self
causes recruitment of inflammatory cells (Zouki
et al., 1999). The molecular mechanisms leading
to a recruitment of CD4-positive lymphocytes are
un known so far. Interestingly, it has been shown
that ET-1 induces the expression of E-selection
and intracellular adhesion molecule-1, facilitating
the migration of inflammatory cells (Zouki
et al.,1999). In the present study we have
demonstrated that administration of bosentan
significantly suppressed the severity of the
inflammatory infiltration in BALF and lung tissue.
Bosentan significantly suppressed the number
of total cells, macrophages, lymphocytes and
neutrophils in BALF. Significant decrease in MPO
activity in lung tissue, total protein content in BALF,
wet/dry lung weight ratio (edema marker) and
decreased infiltration of inflammatory cells in lung
tissue sections on day 7 of post bleomycin
instillation supported these findings. Therefore the
inhibited inflammatory cell infiltration was partly
accountable for the preventive effect of bosentan
on bleomycin induced pulmonary fibrosis.
A number of previous studies reported that the
cellular imbalance between the Reactive Oxygen
Species (ROS) and antioxidant enzymes are
involved in pathogenesis of IPF (Kinnula et al.,
2005). The lung injury caused by the bleomycin
involves the generation of oxidant species and
further damage is probably elicited by the
generation of ROS produced by activated
inflammatory cells, which accumulate in
bleomycin induced pulmonary lesions (Li et al.,
2002). ET-1 may also participate in the
pathogenesis of lung fibrosis through its effects
on cellular apoptosis and oxidant/antioxidant
imbalance. ET-1 was reported to induce reactive
oxygen species in several cell types, including
vascular smooth muscle cells and pericytes
(Fonseca et al., 2011). Recently, it was reported
that endothelin receptor antagonist (Bosentan)
increased the serum antioxidant activity in
cigarette smoke extract induced emphysema in
a rat model (Chen et al., 2010). Interestingly,
emphysema and lung fibrosis are likely to share
many pathogenetic pathways, as suggested by
the strong link with smoking in IPF (Baumgartner
et al., 1997). Bosentan attenuated oxidative stress
and restored cellular antioxidant defense
mechanism (SOD and catalase enzymes) in
experimental myocardial ischemia and
reperfusion (Gupta et al., 2005). In the present
study, we have demonstrated that there was a
significant decrease in SOD and catalase
activities in bleomycin challenged mice which was
restored in bosentan treated mice on day 7 of
post bleomycin challenge.
ET-1 is also profibrotic by stimulating fibroblast
replication, migration, contraction, and collagen
synthesis and secretion while decreasing collagen
degradation . ET-1 was shown to promote the
wound-healing response by stimulating the
production of collagens IV, V, and VII, involved in
reconstitution of the basement membrane and
appropriate wound closure (Fonseca et al., 2011)
. ET-1 may thus play an important role in the initial
injury, inflammatory events and eventual fibrotic
reparative process in lung. The results of RT-PCR69
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studies demonstrated that blockade of ET-
receptor with bosentan significantly decreased
the collagen-I gene expression levels in bleomycin
challenged mice. Significant decrease in
hydroxyproline level, decreased collagen
deposition in Masson’s trichrome and picrosirus
red stained lung tissue sections supported these
findings. ET-1 enhances the conversion of
fibroblasts into contractile myofibroblasts. ET-1
promotes myofibroblast differentiation and
contraction to contribute to the effective matrix
remodelling during tissue repair (Fonseca et al.,
2011). α-SMA is the marker for myofibroblasts,
the findings of gene expression studies revealed
that treatment with bosentan significantly
decreased α-SMA gene expression. This findings
suggested that bosentan inhibits conversion of
fibroblasts into myofibroblasts.
Several studies have implicated MMPs in
human and experimental interstitial lung disease.
In humans IPF levels of MMP-2 (gelatinase-A) and
MMP-9 (gelatinase-B) are elevated in lungs and
BALF fluid of affected patients. MMP-2 and MMP-
9 proteolytically cleave the denatured collagen and
have the ability to cleave the type IV collagen, the
key structural components of basement
membrane (Roderick et al., 2000). Felix et al.
(2006) reported that ET-1 enhances the MMP-2
and MMP-9 activity in osteosarcoma cells and
human osteosarcoma tissue. The present study
demonstrated that inhibition of ET-1 by bosentan
significantly reduces the MMP-2 and MMP-9
activities which were elevated by bleomycin
administration.
CONCLUSION
In summary, ET-1 signaling involved in
pathogenesis of bleomycin induced pulmonary
fibrosis in rats resulted in oxidative stress,
inflammation, MMP activation and extracelluar
matrix deposition. In the present study, we found
that the blockade of ET-1 signaling with bosentan
inhibits the inflammation, oxidative stress, MMP
activation and finally extracelluar matrix
deposition. Bosentan significantly abrogates the
fibrosis suggests that it is useful therapeutic tool
in human IPF.
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